.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
AstraZeneca
Medtronic
Chubb
Mallinckrodt
Farmers Insurance
Merck
Cerilliant
Argus Health

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,919,118

« Back to Dashboard

Which drugs does patent 7,919,118 protect, and when does it expire?


Patent 7,919,118 protects OMONTYS and OMONTYS PRESERVATIVE FREE and is included in one NDA.

This patent has twenty patent family members in fifteen countries.

Summary for Patent: 7,919,118

Title:Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Abstract: The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: --NH--(CH.sub.2).sub..alpha.--[O--(CH.sub.2).sub..beta.].sub..gamma.--O.s- ub..delta.--(CH.sub.2).sub..epsilon.--Y-- wherein .alpha., .beta., .gamma., .delta., and .epsilon. are each integers whose values are independently selected.
Inventor(s): Holmes; Christopher P. (Saratoga, CA), Yin; Qun (Palo Alto, CA), Tumelty; David (Sunnyvale, CA)
Assignee: Affymax, Inc. (
Application Number:10/555,860
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms UsaOMONTYSpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-007Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYSpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-008Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-001Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-004Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-005Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
Takeda Pharms UsaOMONTYS PRESERVATIVE FREEpeginesatide acetateSOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-006Mar 27, 2012DISCNNoNo► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,919,118

PCT Information
PCT FiledMay 12, 2004PCT Application Number:PCT/US2004/014887
PCT Publication Date:November 25, 2004PCT Publication Number: WO2004/100997

Non-Orange Book Patents for Patent: 7,919,118

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,592,365Spacer moiety for poly(ethylene glycol) modified peptide based compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,919,118

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand563042► Subscribe
New Zealand543934► Subscribe
Norway20055848► Subscribe
MexicoPA05012314► Subscribe
South Korea101160611► Subscribe
South Korea20060023123► Subscribe
Japan2012140466► Subscribe
Japan2007500218► Subscribe
Iceland8168► Subscribe
Israel171885► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Chubb
Boehringer Ingelheim
Chinese Patent Office
Julphar
Merck
US Army
Cerilliant
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot